Erschienen in:
01.05.2013 | Symposium: Special Considerations for TKA in Asian Patients
Painful Patellar Clunk or Crepitation of Contemporary Knee Prostheses
verfasst von:
Won Chul Choi, MD, PhD, Keun-Jung Ryu, MD, Sahnghoon Lee, MD, PhD, Sang Cheol Seong, MD, PhD, Myung Chul Lee, MD, PhD
Erschienen in:
Clinical Orthopaedics and Related Research®
|
Ausgabe 5/2013
Einloggen, um Zugang zu erhalten
Abstract
Background
Painful patellar clunk or crepitation (PCC) is a resurgent complication of contemporary posterior-stabilized TKA. The incidence, time to presentation, causes, and treatment of PCC still remain controversial.
Questions/purposes
We therefore (1) compared the incidence of PCC with five contemporary TKA designs, (2) evaluated the time to presentation, (3) identified possible etiologies, and (4) determined recurrence rate and change in knee functional scores after treatment for PCC.
Methods
We reviewed 580 patients who had 826 posterior-stabilized TKAs involving five different designs. The incidences of PCC were compared among the prostheses. The knees were divided into two groups depending on the development of PCC, and possible etiologic factors of PCC, including prosthesis design and surgical or radiographic variables, were compared between groups. We investigated the onset time of PCC and evaluated treatment results by knee outcome scores. Minimum followup was 2.0 years (mean, 3.9 years; range, 2.0–9.8 years).
Results
The PCC incidence was higher in the Press-Fit Condylar® Sigma® Rotating Platform/Rotating Platform-Flex Knee System (11 of 113 knees, 9.7%) than in the others (seven of 713 knees, 1.0%). Increased risk of PCC was associated with using a specific prosthesis and patellar retention. PCC occurred in all cases within a year after TKA (mean, 7.4 months). Arthroscopic treatment (16 knees) and patellar replacement (two knees) improved knee scores, with no recurrence observed over an average followup of 29 months.
Conclusions
Prosthesis design and patellar retention were associated with PCC. Surgery resolved the PCC.
Level of Evidence
Level III, therapeutic study. See Instructions to Authors for a complete description of levels of evidence.